Clinical significance in the change of decline in ALSFRS-R

@article{CastrilloViguera2010ClinicalSI,
  title={Clinical significance in the change of decline in ALSFRS-R},
  author={Carmen Castrillo-Viguera and Daniela L. Grasso and Elizabeth Simpson and Jeremy M. Shefner and Merit Cudkowicz},
  journal={Amyotrophic Lateral Sclerosis},
  year={2010},
  volume={11},
  pages={178 - 180}
}
Our objective was to survey ALS clinicians and researchers regarding what percentage reduction in the ALSFRS-R (Amyotrophic Lateral Sclerosis Functional Rating Scale – Revised) slope they would consider clinically meaningful. A nine-question survey was provided to 65 members of the Northeast ALS Consortium (NEALS). They were asked to rate the clinical relevance of 10–50% changes in decline of the ALSFRS-R slope on a seven-point scale (1–7), where 1=‘not at all clinically meaningful’, 4… Expand

Topics from this paper

A retrospective investigation of the relationship between baseline covariates and rate of ALSFRS-R decline in ALS clinical trials
TLDR
The findings of this retrospective study, which are novel in the clinical trial time frame, contribute to the understanding of disease trajectory in ALS and can be used to guide future design and analysis of clinical trials. Expand
Heterogeneity in ALSFRS-R decline and survival: a population-based study in Italy
TLDR
It is confirmed that ALSFRS-R decline is not homogeneous among ALS patients and during the disease, and factors influencing this trend may not match with those affecting survival. Expand
Relationships between slow vital capacity and measures of respiratory function on the ALSFRS-R
TLDR
The higher correlation between %predicted SVC and specific ALSFRS-R symptom scores in patients with rapidly versus more slowly progressing disease reinforces the importance of continually monitoring respiratory function throughout the disease course. Expand
Trajectories of impairment in amyotrophic lateral sclerosis: Insights from the Pooled Resource Open‐Access ALS Clinical Trials cohort
TLDR
Variable curvilinearity of ALSFRS‐R trajectories confounds interpretation in clinical studies that assume linear decline and is better used as a multidimensional measure. Expand
Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: Subgroup analysis of demographic and clinical characteristics
TLDR
The observed benefit of 300- vs. 50-mg dexpramipexole on functional decline and survival was generally consistent among subjects regardless of baseline characteristics. Expand
Amyotrophic lateral sclerosis disease progression model
  • R. Gomeni, M. Fava
  • Medicine
  • Amyotrophic lateral sclerosis & frontotemporal degeneration
  • 2014
TLDR
A longitudinal model to describe amyotrophic lateral sclerosis disease progression using the revised Amyotrophic Lateral Sclerosis Functional Rating Scale and a probabilistic model to estimate the presence of clusters of trajectories in ALS progression over 12 months of treatment showed that the degree of ALS disease progression quantified by the ALSFRS-R symptomatic change on placebo is highly heterogeneous. Expand
Exploring the diagnosis delay and ALS functional impairment at diagnosis as relevant criteria for clinical trial enrolment*
TLDR
At time of inclusion in therapeutic trial closed to diagnosis, ΔFS or diagnosis delay may discriminate the rate of progression, according to diagnosis delay. Expand
Unraveling the Complexity of Amyotrophic Lateral Sclerosis Survival Prediction
TLDR
The dimensionality and fluctuating predictors of ALS survival must be considered when developing predictive models for clinical trial development or in-clinic usage and is needed for population and personalized forecasting of survival. Expand
Non-self-sufficiency as a primary outcome measure in ALS trials
TLDR
NSS status at four weeks predicted survival even after adjustment for ALSFRS-R total score, age, gender, site of onset, disease duration, BMI, and FVC, and ‘Walking’ was the only predictor of survival when adjusting for all covariates. Expand
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
TLDR
The primary efficacy outcome was the change in ALSFRS-R score from the baseline to 24 weeks (or at discontinuation if this was after the third cycle) after randomisation and the least-squares mean difference between groups was 2·49 (SE 0·76, 95% CI 0·99-3·98) in favour of edaravone. Expand
...
1
2
3
4
5
...

References

SHOWING 1-8 OF 8 REFERENCES
Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials
TLDR
The data provided by the placebo patients who participated in the ALS CNTF Treatment Study (ACTS) is used to demonstrate the robustness, test-retest reliability and consistency of the ALSFRS as employed in a large, multicenter clinical trial. Expand
The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function
TLDR
A revised version of the ALSFRS, which incorporates additional assessments of dyspnea, orthopnea, and the need for ventilatory support is validated, indicating that the quality of function is a strong determinant of quality of life in ALS. Expand
Outcome measures for early phase clinical trials
TLDR
The ALSFRS‐R most strongly predicted survival and provided the most complete data, but large changes may be necessary before patients perceive treatment effects, but all could be used in short‐duration, early phase trials. Expand
Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial
  • P. Leigh, M. Swash, +7 authors L. H. van den Berg
  • Medicine
  • Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases
  • 2004
TLDR
The panel recommended the use of the ALS Functional Rating Scale (ALSFRS‐R) to measure primary endpoints and a review of other key issues in this area including regional variations in the epidemiology, diagnosis and management of ALS. Expand
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
  • R. Miller, J. Mitchell, M. Lyon, D. Moore
  • Medicine
  • Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases
  • 2003
TLDR
The efficacy of riluzole in prolonging survival, and in delaying the use of surrogates (tracheostomy and mechanical ventilation) to sustain survival, is examined. Expand
Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis
TLDR
Analysis of the combined data from the phase II and III trials revealed a significantly more rapid decline of forced vital capacity in patients treated with gabapentin. Expand
ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord
  • 2004
Phase II/III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis
  • 2001